Skip to content

US · 21 CFR

21 CFR 601.93

Postmarketing safety reporting.

21 CFR Part 601 › Subpart H—Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible

Section text

Biological products approved under this subpart are subject to the postmarketing recordkeeping and safety reporting applicable to all approved biological products.

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time